Anastrozole and tamoxifen yield similar disease recurrence outcomes in postmenopausal women with ductal carcinoma in situ (DCIS), but side-effect profiles of the two vary, making anastrozole suitable for women with contraindications to tamoxifen, the phase III IBIS-II DCIS (International Breast Cancer Intervention-II DCIS) trial has shown.
Adjuvant capecitabine therapy significantly improved disease-free survival (DFS) in HER2-negative primary breast cancer patients with residual invasive disease after neoadjuvant chemotherapy (NAC), according to results of the CREATE-X* trial presented at the recent San Antonio Breast Cancer Symposium 2015 in San Antonio, Texas, US.
Adjuvant treatment with a low dose of denosumab decreased the risk of fractures and improved disease-free survival (DFS) in postmenopausal women with early, HR-positive breast cancer, when added to aromatase inhibitor (AI) therapy.
Pearl Toh spoke with Dr Teh Ming Ming, senior consultant at the Department of Endocrinology, Singapore General Hospital (SGH), on the major challenges of diagnosing and managing diabetes in primary care, in conjunction with the World Diabetes Day on 14 November. Awareness of the symptoms of diabetes is important, and patients should be empowered to manage their conditions.
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.